Posted by Michael Wonder on 19 Feb 2025
Selpercatinib for the treatment of patients with advanced RET fusion positive non-small-cell lung cancer
19 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of adults with advanced RET fusion positive non-small-cell lung cancer.
Selpercatinib is recommended as an option for the second-line treatment of adults with advanced RET fusion positive non-small-cell lung cancer who have not been treated with a RET inhibitor only if Eli Lilly provides selpercatinib according to the commercial arrangement.
